Genmab A/S announced plans to begin four studies of ofatumumab in chronic lymphocytic leukaemia (CLL) and follicular non-Hodgkin's lymphoma (NHL) this year.

"Genmab and GSK have worked diligently to expand the ofatumumab development programme to maximize the value of the antibody for patients and shareholders since our collaboration began," said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab. "The new studies we are initiating this year will examine the potential of ofatumumab in Japan as well as a number of new treatment settings - retreatment, maintenance and front line with chlorambucil."

This open-label, parallel-arm study will include 444 patients with previously untreated CLL. Patients in the study will be randomized to receive ofatumumab in combination with chlorambucil or chlorambucil alone. Patients receiving ofatumumab in combination with chlorambucil will receive one infusion of ofatumumab at 300 mg, one infusion at 1000 mg a week later, followed by up to 11 monthly infusions at 1000 mg. Patients will be evaluated for disease status one month following last treatment then every 3 months for 5 years.

The primary objective of the study is to evaluate the progression free survival of ofatumumab in combination with chlorambucil therapy versus chlorambucil therapy alone for the treatment of front line CLL.


This study will examine the retreatment and maintenance treatment of refractory CLL patients who participated in the ongoing Phase III CLL study and had disease progression following at least an objective response or stable disease during a 24 week treatment period of ofatumumab. Eligible patients will receive one infusion of ofatumumab at 300 mg followed by 7 once weekly infusions at 2000 mg. Maintenance treatment will consist of 24 once monthly infusions of 2000 mg of ofatumumab. The primary objective of this study is to estimate the proportion of objective responses over 52 weeks.

This study will examine the retreatment and maintenance treatment of refractory follicular NHL patients who participated in the ongoing Phase III NHL study and had disease progression following at least 6 months objective response to or stable disease on ofatumumab. Eligible patients will receive one infusion of ofatumumab at 300 mg followed by 7 once weekly infusions at 1000 mg. Maintenance treatment will consist of one 1000 mg infusion every two months for two years. The primary objective of this study is to evaluate the safety of ofatumumab retreatment and maintenance treatment.

Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukaemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.